Healthcare - Biotechnology - NASDAQ - US
$ 4.79
-11 %
$ 406 M
Market Cap
-1.95
P/E
CASH FLOW STATEMENT
-150 M
OPERATING CASH FLOW
27.7 M
INVESTING CASH FLOW
213 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verve Therapeutics, Inc.
| Net Income | -200 M |
| Depreciation & Amortization | 5.46 M |
| Capital Expenditures | -9.28 M |
| Stock-Based Compensation | 35.1 M |
| Change in Working Capital | 17.7 M |
| Others | 6.04 M |
| Free Cash Flow | -159 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (200.1) | (157.4) | (120.3) | (45.7) | (19.3) |
| Depreciation & Amortization | 5.5 | 2.8 | 1.5 | 1.3 | 0.1 |
| Deferred Income Tax | 0 | 0 | 1.5 | 0.4 | 72 K |
| Stock Based Compensation | 35.1 | 22.5 | 7.1 | 0.8 | 0.4 |
| Other Operating Activities | (7.8) | 1.4 | 35.2 | 5.2 | 8.7 |
| Change in Working Capital | 17.7 | 8.4 | (2.9) | 2.6 | 2.7 |
| Cash From Operations | (149.5) | (122.3) | (77.9) | (35.3) | (7.4) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (9.3) | (13.2) | (4.4) | (3.4) | (1.9) |
| Other Items | 37.0 | (142.7) | (234.7) | (47.7) | (10.9) |
| Cash From Investing Activities | 27.7 | (156.0) | (239.1) | (51.1) | (12.8) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.1 | 2.5 | 91.9 | 92.6 | 18.0 |
| Cash From Financing Activities | 212.6 | 329.0 | 377.1 | 92.6 | 18.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 90.7 | 50.7 | 60.1 | 6.2 | (2.2) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (158.8) | (135.6) | (82.2) | (38.7) | (9.3) |